Five years of creating medicines, instilling hope, and overcoming steep challenges—all with the singular goal of improving the lives of nano-rare disease patients. Along the way, we’ve proven that WE CAN treat these patients safely and effectively, delivering significant benefit. But what else have we discovered throughout this journey?

Thank you to Hongene Biotech Corporation for sponsoring this 5-Year Anniversary episode. On This Episode We Discuss:

- We CAN do this

- n-Lorem is proof of the value of investing in science

- We can treat nano-rare patients safely

- The nano-rare patient population is large

- We must introduce genomic sequencing into newborn evaluation

- Most nano-rare diseases are more prevalent than we think

- Most diseases are a composite of multiple mutations in one or more genes

- A non-profit model in which patients are treated irrespective of their financial status is feasible

- Nano-rare mutations are spread throughout the genome

- Nano-rare mutations can affect any organ

- Essentially all types of mutations can cause nano-rare diseases

- Most nano-rare patients express severe, chronic, debilitating, progressive diseases

- The journey to diagnosis is often unique, long, and perilous

- Significant benefit can be achieved

- ASOs administrated intrathecally for CNS diseases can result in profound benefit - ASOs can result in durable benefit

- Many patients require allele-selective ASOs

- The community is strong

- Industrialized processes created by n-Lorem is delivering great value

- The modified cross-over clinical design created by n-Lorem is delivering high quality data

- If we raise the funds, we can meet the demand Donate: www.nlorem.org/donate

Walt Whitman’s 1855 poem, I Sing the Body Electric, is a celebration of the human body and its intrinsic connection to the universe. During that era, scientists were just beginning to understand that humans are, indeed, electrical beings. Whitman’s deliberate use of the word "electric" in his tribute to the human body was quite remarkable, as the term was not widely used at the time and electricity for human use was still in the experimental stage. With that in mind, the poem’s title serves as both a poetic and scientific statement.

Many have compared great science to art, but we believe it is more akin to poetry. A poet distills intricate concepts, stories, and emotions into the most concise, impactful expression—cutting through the noise to reach the heart and soul of the matter. Similarly, great scientists achieve this with their work. Together, scientists and patients contribute their own verses to the epic poem of understanding known as science.

This episode of the Patient Empowerment Program podcast is proudly sponsored by Hongene Biotech. With more than 26 years of experience in the nucleic acid industry, Hongene is a specialized CDMO and raw materials supplier committed to providing high-quality and high value products and services with the best in class lead times.

Make Hope Possible and donate, today www.nlorem.org/donate

Episode sponsor: Hongene Biotech https://www.hongene.com/

Join Stan Crooke, n-Lorem founder, CEO, and host of the Patient Empowerment Program Podcast, alongside Amy Williford, Sr. Director of Communications and Donor Relations, for a special episode.

In this post-colloquium Q&A, Stan recaps the 2024 Nano-rare Patient Colloquium and the progress n-Lorem has made as the organization nears its 5-year anniversary, shares his candid reflections on the event, and dives into additional thoughts and questions that weren’t covered.

Do you have additional questions? Email podcast@nlorem.org.

Question Bank:

1. 2:15 How do you think the event went this year?
2. 6:05 Were observations of benefit expected in patients so quickly?
3. 9:47 What do you expect the number of patients treated to be next year?
4. 10:57 Do you have a message to supporters?
5. 12:30 Were there any disappointments from the colloquium?
6. 13:21 What are the most important things that n-Lorem has learned this year?
7. 16:13 Do you think n-Lorem’s processes will be outlined every year at the event?
8. 18:05 How is AI incorporated at n-Lorem?
9. 19:10 Does your recently announced deal with GondolaBio reflect the sustainability strategy discussed at the event?
10. 20:53 n-Lorem is celebrating 5 years in 2025. Did you expect the foundation to be where it is today?
11. 21:28 Does n-Lorem plan to expand into Europe and elsewhere?

Make hope possible with a donation.